Unraveling the Mechanism of Curculiginis Rhizoma in Suppressing Cisplatin Resistance in Non-Small Cell Lung Cancer: An Experimental Study
Xin Huang,Meng Wang,Baochen Zhu,Yu Hao,Ruoyu Gao,Wenhui Liu,Jiaojiao Cheng,Guodong Hua,Chunmiao Xue
DOI: https://doi.org/10.2147/ott.s448636
IF: 4
2024-06-13
OncoTargets and Therapy
Abstract:Xin Huang, 1, &ast Meng Wang, 1, &ast Baochen Zhu, 1, &ast Yu Hao, 2 Ruoyu Gao, 2 Wenhui Liu, 2 Jiaojiao Cheng, 1 Guodong Hua, 1 Chunmiao Xue 1 1 Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, People's Republic of China; 2 School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Guodong Hua; Chunmiao Xue, Email ; Introduction: Non-small cell lung cancer (NSCLC) stands as one of the most prevalent malignancies, and chemotherapy remains the primary treatment for advanced stages. However, the high expression of ABC binding cassette transporters, including MRP, P-gp, and LRP, along with multidrug resistance proteins, has been identified as a significant factor contributing to decreased chemotherapy drug sensitivity. This study aims to explore the impact and underlying mechanisms of Curculiginis Rhizoma [Hypoxidaceae; Curculigo orchioides Gaertn.] (CR) in combination with cisplatin on improving chemoresistance mediated by ABC binding cassette transporters and multidrug resistance proteins in NSCLC. Methods and Results: To unravel the relationship between JNK, MRP, P-gp, and LRP in NSCLC and gain insights into the regulatory mechanism of CR, this study employs an integrated approach encompassing bioinformatics, molecular docking, molecular dynamics, animal and cellular experiments. Bioinformatics analysis revealed a significant increase in the expression levels of JNK, MRP, P-gp, and LRP subtypes in multidrug-resistant non-small cell lung cancer. Subsequent animal experiments have shown that the combination of CR with cisplatin can improve the survival rate of lung cancer mice. Molecular docking and molecular dynamics analyses demonstrated favorable binding interactions between curculigoside and the aforementioned subtypes of JNK, MRP, P-gp, and LRP. In cellular experiments, the combination of cisplatin with both curculigoside and CR extract resulted in a notable decrease in cell viability and downregulation of the expression of JNK1, JNK2, MRP1, MRP2, MRP4, P-gp, and LRP1 in A549/cis cells. Conclusion: Remarkably, curculigoside exerted a significant downregulation effect on the expression levels of JNK1, MRP1, MRP2, MRP4, and LRP1. CR, particularly its main effective metabolite, curculigoside, has the potential to enhance the sensitivity of non-small cell lung cancer to cisplatin by regulating levels of JNK/MRP/LRP/P-gp and mitigating multidrug resistance. Keywords: non-small cell lung cancer, curculiginis rhizoma, CR, curculigoside, multidrug resistance, cisplatin resistance, ABC binding cassette transporter, multidrug resistance proteins Non-small cell lung cancer (NSCLC) is a common and aggressive subtype of lung cancer, characterized by high malignancy, recurrence risk, and heightened sensitivity to radiotherapy and chemotherapy. Despite the advancements in treatment modalities, such as chemotherapy, molecular targeted therapies, and immune checkpoint inhibitors, drug resistance remains a significant obstacle in the management of NSCLC. Multidrug resistance proteins, including multidrug resistance protein (MRP), P-glycoprotein (P-gp), and lung resistance-associated protein (LRP), are pivotal downstream regulators involved in the development of secondary multidrug resistance in NSCLC. 1–3 These transporters hinder drug entry into cancer cells, leading to diminished drug sensitivity and reduced treatment efficacy. ABC transporters are proteins that can use the energy generated by ATP hydrolysis for transmembrane transport of different substrates. These proteins are typically located on the cell membrane and can protect cells from harmful toxins. 4 Moreover, ABC transporters are energy-dependent transport systems for periplasmic solute-binding proteins (SBPs), activated by ATP hydrolysis, 5 which can transport solutes from the inside of the cell to the outside. Up to now, based on the sequences and structures of ABC domains, 48 members of the ABC transporter protein family have been identified and classified into seven families, labeled A to G. ABC transporters are further categorized into three types: importers (in prokaryotes), exporters (in eukaryotes and prokaryotes), and ABCs involved in DNA repair and translation. Therefore, they can also affect the pharmacokinetics of chemotherapy. 6 Among them, multidrug resistance protein 1 (MDR1), also known as p-glycoprotein(P-gp), has a gene named ABCB1. The gene for multidrug resistance-associated protein (MRP) is ABCC. 7 LRP is different from MRP -Abstract Truncated-
oncology,biotechnology & applied microbiology